{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-a/prescribing-information/anti-pruritics/","result":{"pageContext":{"chapter":{"id":"508e578c-aa68-5cdb-aa90-ef8889919c08","slug":"anti-pruritics","fullItemName":"Anti-pruritics","depth":2,"htmlHeader":"<!-- begin field 1193e960-10cf-4945-b6c5-a803b9b8adef --><h2>Anti-pruritics</h2><!-- end field 1193e960-10cf-4945-b6c5-a803b9b8adef -->","summary":"","htmlStringContent":"<!-- begin item 9fd37fe9-502b-4948-b106-797d7fb9cb34 --><!-- end item 9fd37fe9-502b-4948-b106-797d7fb9cb34 -->","topic":{"id":"29ac65ab-afdd-58a1-bb07-9c101977d24d","topicId":"580cfa7a-647b-439a-8f8c-493cb6bd4332","topicName":"Hepatitis A","slug":"hepatitis-a","lastRevised":"Last revised in January 2021","chapters":[{"id":"d47cd8cf-fe05-5aa4-997b-01a20519d12f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bbe6550-f4f5-5279-9e9e-04b38f9dc672","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75791cbd-6d69-555e-83e8-9ac8cca25c50","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c0ae1a2d-febe-5ec7-821a-0616062456ee","slug":"changes","fullItemName":"Changes"},{"id":"434eb73d-f60d-5f1f-ba10-5aa77d904da1","slug":"update","fullItemName":"Update"}]},{"id":"242c9e8c-5867-5598-9168-62160e8ae293","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6c2f4656-f9e8-56be-aa43-3f6a9aa45aa8","slug":"goals","fullItemName":"Goals"},{"id":"71c0a726-22c7-568b-b925-d10cc97ace3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"70e8a1cd-fd5b-50d7-8ce4-b6f29981218d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"37bb7a58-62c9-52be-b97c-7b99f8317f12","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"badbd40f-9ce6-5f8a-9f65-8be03bc8d3fe","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed9f7297-1f33-5365-8e4f-3844542af45d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a11034-e31c-5039-8ca7-b463c00b2039","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a2206363-5f44-5348-b469-07b49a6a9647","slug":"definition","fullItemName":"Definition"},{"id":"dd1ca873-1bf9-500d-a574-fc92c8589e62","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bdd89354-2f0b-564c-b589-cb043e32b99c","slug":"transmission","fullItemName":"Transmission"},{"id":"8e72bb81-12fd-5a0e-976b-d18d62788974","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ab3f5823-00db-5e27-a434-c323c357ab02","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e879b74c-3d75-59c5-806e-4b39a6e72901","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"94f8b729-5e94-57ee-b96e-ca1561614640","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6b32fed7-c15e-5976-adc6-692994cbab9e","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"2503640c-54cf-53e1-b29c-fc9c19cbd52a","slug":"investigations","fullItemName":"Investigations"},{"id":"88a35298-3760-53b6-b4ff-b9e0677b4df3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9ba7b244-14ec-5fd1-9b2b-151b9c48bfab","fullItemName":"Management","slug":"management","subChapters":[{"id":"1a3874e3-8562-5ca6-8c97-4d9a2a009e75","slug":"prevention-of-infection-with-hepatitis-a","fullItemName":"Scenario: Prevention of infection with hepatitis A"},{"id":"49c1d671-61dd-5a60-974f-069b03d80d11","slug":"managing-hepatitis-a-infection","fullItemName":"Scenario: Managing hepatitis A infection"},{"id":"449ffa79-3397-54a1-a4d5-0efa55ee889f","slug":"contact-with-hepatitis-a","fullItemName":"Scenario: Contact with hepatitis A"}]},{"id":"8ffd203a-96db-5a38-a7bd-0186b97b6600","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"7d022e5d-ab4e-50bf-b90f-5611cf3a17db","slug":"hepatitis-a-vaccine","fullItemName":"Hepatitis A vaccine"},{"id":"7d0e86fd-3666-5a09-b539-4497227285ee","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0ee2b156-78a9-52f6-ab80-fff22c46ff66","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"508e578c-aa68-5cdb-aa90-ef8889919c08","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"bf6b787f-fbb7-5d8d-bd85-cfe063c76fcd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e0bba353-de5a-55b9-9171-a677ecc4b97a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2571e87f-4ad0-5f6d-8c0e-8c9c86054278","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"94bd9363-8cd1-5ba6-8fd3-11f5a3ce29dd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2db0f1a2-7d4b-5fd2-a8bf-db32553e5b89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"29233885-dedb-5c3b-ba7e-1aae299ecfe2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0a3a365f-c89a-5f1e-8ce5-1078ade19779","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1afe9613-76a4-50b9-8941-c2a2ebec23cc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8ffd203a-96db-5a38-a7bd-0186b97b6600","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d28739f2-88b1-5727-85ab-73fc342e909b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 16217013-09f7-44c5-bec4-aafb016c638d --><h3>Contraindications and cautions</h3><!-- end field 16217013-09f7-44c5-bec4-aafb016c638d -->","summary":"","htmlStringContent":"<!-- begin item d71ad14c-85d7-4c34-b603-aafb016c633c --><!-- begin field 96553bb9-d027-4c25-86df-aafb016c638d --><h4>Chlorphenamine</h4><ul><li><strong>Sedating antihistamines should be used with caution </strong><strong>in people with:</strong><ul><li>Liver dysfunction — chlorphenamine can be used in people whose metabolic and synthetic function is unaffected (such as in mild hepatitis). However, seek specialist advice before using chlorphenamine in people with moderate hepatic impairment. It must be avoided in people with severe hepatic impairment, such as those with cirrhosis or encephalopathy who may decompensate, because of its sedative effects.</li><li>Urinary retention, prostatic hypertrophy, angle-closure glaucoma, or pyloroduodenal obstruction — if possible, avoid using sedating antihistamines because of their significant antimuscarinic activity (particularly in elderly people).</li><li>Epilepsy — avoid chlorphenamine if possible, as it may reduce the seizure threshold.</li><li>Pregnancy — There is currently no evidence of an increased risk of fetal toxicity following chlorphenamine use in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">UKTIS, 2019b</a>].</li><li>Breastfeeding — the UK Drugs in Lactation Advisory Service states that if a sedating antihistamine is needed, chlorphenamine is preferred due to extensive clinical experience of safe use in breastfeeding. There is a possible risk of sedation in the infant, who should be monitored for drowsiness. The Summary of Product Characteristics for chlorphenamine states that it should not be used in breastfeeding unless considered medically essential. See the <a data-hyperlink-id=\"a00e3c8f-bef5-4025-bda1-a99300077ba3\" href=\"http://www.midlandsmedicines.nhs.uk/\">UKMI lactation advisory service</a> website for more information.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">North-Lewis, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 96553bb9-d027-4c25-86df-aafb016c638d --><!-- end item d71ad14c-85d7-4c34-b603-aafb016c633c -->","subChapters":[]},{"id":"d6f3c22d-faa3-5a59-8a3d-ee4ef87b9113","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 418aed2f-8ba4-4eb9-a5c4-aafb016c7095 --><h3>Adverse effects</h3><!-- end field 418aed2f-8ba4-4eb9-a5c4-aafb016c7095 -->","summary":"","htmlStringContent":"<!-- begin item e441a3fc-5895-42cf-94e4-aafb016c7053 --><!-- begin field 019ad34b-f6d2-4d9d-b3e4-aafb016c7095 --><p><strong>The most commonly reported adverse effects </strong>are nervous system disorders:</p><ul><li>Elderly people are particularly susceptible (and so lower doses are recommended).</li><li>Sedating antihistamines may cause drowsiness.</li><li>Anticholinergic adverse effects may also occur, for example blurred vision and dry mouth.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2016b</a>]</p><!-- end field 019ad34b-f6d2-4d9d-b3e4-aafb016c7095 --><!-- end item e441a3fc-5895-42cf-94e4-aafb016c7053 -->","subChapters":[]},{"id":"e49b52eb-90c9-5733-8d83-51a29eca1b03","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field da013b29-3def-45b7-b3ea-aafb016c7ff7 --><h3>Drug interactions</h3><!-- end field da013b29-3def-45b7-b3ea-aafb016c7ff7 -->","summary":"","htmlStringContent":"<!-- begin item 1721480d-aae3-4c36-840b-aafb016c7f71 --><!-- begin field c3fe5668-f672-4a2c-bfe7-aafb016c7ff7 --><p><strong>Key drug interactions with chlorphenamine include:</strong></p><ul><li><strong>Hypnotics and anxiolytics </strong>— increased sedative effects.</li><li><strong>Phenytoin</strong> — chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity.</li><li><strong>MAOIs </strong>—the anticholinergic effects of chlorphenamine are intensified by MAOIs. Do not prescribe chlorphenamine to a person who has been treated with MAOIs within the last fourteen days.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field c3fe5668-f672-4a2c-bfe7-aafb016c7ff7 --><!-- end item 1721480d-aae3-4c36-840b-aafb016c7f71 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}